The Globe and Mail reports in its Monday, April 29, edition that Desjardins Securities analyst John Chu began coverage on Aurora Cannabis with a "buy" rating and $16.50 share target. The Globe's David Leeder writes in the Eye On Equities column that analysts on average target the shares at $13.91. Mr. Chu says in a note: "Aurora Cannabis Inc. is uniquely positioned to dominate the domestic medical market and, in turn, the international medical market. We believe it has the size, quality standards, technology and established medical brand and patient data which it can leverage overseas, where it has the broadest reach geographically of any LP. Once the company establishes a foothold internationally on the medical side, this should position it very well when/if the international market legalizes recreational use. Aurora is no slouch on the recreational side as it has the second highest market share thus far at 13 per cent. The company's best practices philosophy, together with the addition of activist shareholder Nelson Peltz as a strategic advisor, should eventually lead to a partnership with a major [consumer packaged goods] player."